Corcept Therapeutics Inc. (CORT) shares climbed sharply on Thursday, rising 14.20 percent, or $5.15, after the company announced positive results from its pivotal Phase 3 ROSELLA trial in platinum-resistant ovarian cancer.
The study met its primary endpoint of overall survival, showing that patients treated with relacorilant plus nab-paclitaxel experienced a 35 percent reduction in the risk of death compared with those receiving nab-paclitaxel alone.
The stock was trading at $41.46 after opening at $41.62, compared with a previous close of $36.31 on the Nasdaq. Shares moved between $40.46 and $43.50 during the session. The bid was around $40.51, and the ask was near $44.57.
Trading volume rose to about 2,853,682 shares, above the average volume of 1,501,011. Corcept Therapeutics' 52-week range is $32.99 to $117.33.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.